Rong MS - Amphastar Senior Production
| AMPH Stock | USD 44.55 0.46 1.04% |
Executive
Rong MS is Senior Production of Amphastar P
| Age | 65 |
| Address | 11570 6th Street, Rancho Cucamonga, CA, United States, 91730 |
| Phone | 909 980 9484 |
| Web | https://www.amphastar.com |
Amphastar Management Efficiency
The company has return on total asset (ROA) of 0.0867 % which means that it generated a profit of $0.0867 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2385 %, meaning that it created $0.2385 on every $100 dollars invested by stockholders. Amphastar's management efficiency ratios could be used to measure how well Amphastar manages its routine affairs as well as how well it operates its assets and liabilities. The Amphastar's current Return On Tangible Assets is estimated to increase to 0.16. The Amphastar's current Return On Capital Employed is estimated to increase to 0.16. As of now, Amphastar's Other Current Assets are increasing as compared to previous years. The Amphastar's current Intangible Assets is estimated to increase to about 640.6 M, while Other Assets are projected to decrease to under 35.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Eric Benevich | Neurocrine Biosciences | 59 | |
| Christopher OBrien | Neurocrine Biosciences | 67 | |
| Max Reinhardt | Pacira BioSciences, | 53 | |
| MBA MD | Supernus Pharmaceuticals | 63 | |
| David Boyer | Neurocrine Biosciences | 45 | |
| Jane Sorensen | Neurocrine Biosciences | N/A | |
| Richard Kahr | Pacira BioSciences, | N/A | |
| Volker Braun | Evotec SE ADR | N/A | |
| Chad Gassert | ANI Pharmaceuticals | 48 | |
| Jessica Novak | Evolus Inc | N/A | |
| Glenn David | Phibro Animal Health | 52 | |
| Blair Jackson | Alkermes Plc | 51 | |
| Charles Laranjeira | Pacira BioSciences, | 58 | |
| Ian Hunneyball | Evotec SE ADR | 74 | |
| Julie Cooke | Neurocrine Biosciences | 58 | |
| Bart Dunn | Collegium Pharmaceutical | N/A | |
| Aurelie Dalbiez | Evotec SE ADR | 47 | |
| Greg Martini | Ironwood Pharmaceuticals | N/A | |
| Larry Miller | Phibro Animal Health | 60 | |
| Taylor Raiford | Supernus Pharmaceuticals | N/A | |
| Christian Wojczewski | Evotec SE ADR | 52 | |
Management Performance
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.0867 |
Amphastar P Leadership Team
Elected by the shareholders, the Amphastar's board of directors comprises two types of representatives: Amphastar inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amphastar. The board's role is to monitor Amphastar's management team and ensure that shareholders' interests are well served. Amphastar's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amphastar's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ziping Luo, Chief Chairman | ||
| Peter Langosh, VP Audit | ||
| MBA MPH, Executive Operations | ||
| MP MBA, Senior Operations | ||
| William MBA, Executive CFO | ||
| Rong MS, Senior Production | ||
| Dan MBA, Senior Communication | ||
| Jacob MBA, Marketing Sales | ||
| Yongfeng Zhang, President, CoFounder |
Amphastar Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amphastar a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.0867 | ||||
| Profit Margin | 0.22 % | ||||
| Operating Margin | 0.30 % | ||||
| Current Valuation | 2.5 B | ||||
| Shares Outstanding | 48.08 M | ||||
| Shares Owned By Insiders | 22.40 % | ||||
| Shares Owned By Institutions | 74.70 % | ||||
| Number Of Shares Shorted | 4.34 M | ||||
| Price To Earning | 972.67 X |
Currently Active Assets on Macroaxis
When determining whether Amphastar P offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amphastar's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amphastar P Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amphastar P Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amphastar P. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amphastar. If investors know Amphastar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amphastar listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.14) | Earnings Share 3.01 | Revenue Per Share 14.942 | Quarterly Revenue Growth 0.059 | Return On Assets 0.0867 |
The market value of Amphastar P is measured differently than its book value, which is the value of Amphastar that is recorded on the company's balance sheet. Investors also form their own opinion of Amphastar's value that differs from its market value or its book value, called intrinsic value, which is Amphastar's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amphastar's market value can be influenced by many factors that don't directly affect Amphastar's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amphastar's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amphastar is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amphastar's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.